Tachykinin receptor antagonists in clinical trials
Tachykinins (TKs) are small peptides widely distributed in the central and peripheral nervous systems where they act as neurotransmitters. Potent and selective TKs antagonists have been developed in the last 20 years and many efforts have been made to prove their efficacy in the treatment of various...
Gespeichert in:
| Veröffentlicht in: | Expert opinion on investigational drugs 2009-12, Vol.18 (12), p.1843-1864 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1864 |
|---|---|
| container_issue | 12 |
| container_start_page | 1843 |
| container_title | Expert opinion on investigational drugs |
| container_volume | 18 |
| creator | Quartara, Laura Altamura, Maria Evangelista, Stefano Maggi, Carlo A |
| description | Tachykinins (TKs) are small peptides widely distributed in the central and peripheral nervous systems where they act as neurotransmitters. Potent and selective TKs antagonists have been developed in the last 20 years and many efforts have been made to prove their efficacy in the treatment of various diseases. Herein the most prominent results in the clinical development are reported and discussed. For aprepitant, the only compound of this class to have been launched to date, results of clinical studies and postmarketing cost-effectiveness data for the treatment of chemotherapy-induced emesis are discussed. The field is still well active, as currently proof-of-concept studies for indications initially missed (i.e., depression) are ongoing and new targets are under investigation. |
| doi_str_mv | 10.1517/13543780903379530 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_734157083</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734157083</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-a7a9e457267be438c2e151ec26351ef5cbb5598b96d5dcbd8d234a847f4bc1323</originalsourceid><addsrcrecordid>eNp9kM1KAzEUhYMotlYfwI3MztVoMkkmCbqR4h8U3NR1yGQyNnUmqUkG6dsbaUFEcHUu937ncDkAnCN4hShi1whTghmHAmLMBMXwAEwRI6RkNeWHec73MgNkAk5iXENYwUwdgwkSAnMuxBRUS6VX23frrCuC0WaTfCiUS-rNOxtTLPJe9_msVV-kYFUfT8FRl8Wc7XUGXh_ul_OncvHy-Dy_W5SaMJRKxZQwhLKqZo0hmOvK5KeNrmqcpaO6aSgVvBF1S1vdtLytMFGcsI40GuEKz8DlLncT_MdoYpKDjdr0vXLGj1EyTBBlkONMoh2pg48xmE5ugh1U2EoE5XdT8k9T2XOxTx-bwbQ_jn01GbjdAdZ1Pgzq04e-lUltex-6oJy2UeL_8m9-2VdG9WmlVTBy7cfgcnP_fPcFsrmIiQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734157083</pqid></control><display><type>article</type><title>Tachykinin receptor antagonists in clinical trials</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Quartara, Laura ; Altamura, Maria ; Evangelista, Stefano ; Maggi, Carlo A</creator><creatorcontrib>Quartara, Laura ; Altamura, Maria ; Evangelista, Stefano ; Maggi, Carlo A</creatorcontrib><description>Tachykinins (TKs) are small peptides widely distributed in the central and peripheral nervous systems where they act as neurotransmitters. Potent and selective TKs antagonists have been developed in the last 20 years and many efforts have been made to prove their efficacy in the treatment of various diseases. Herein the most prominent results in the clinical development are reported and discussed. For aprepitant, the only compound of this class to have been launched to date, results of clinical studies and postmarketing cost-effectiveness data for the treatment of chemotherapy-induced emesis are discussed. The field is still well active, as currently proof-of-concept studies for indications initially missed (i.e., depression) are ongoing and new targets are under investigation.</description><identifier>ISSN: 1354-3784</identifier><identifier>EISSN: 1744-7658</identifier><identifier>DOI: 10.1517/13543780903379530</identifier><identifier>PMID: 19938899</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Antiemetics - therapeutic use ; anxiety ; Asthma - drug therapy ; chemotherapy-induced emesis ; clinical development ; Clinical Trials as Topic ; depression ; Gastrointestinal Diseases - drug therapy ; Humans ; irritable bowel syndrome ; Mental Disorders - drug therapy ; Morpholines - therapeutic use ; Neurokinin-1 Receptor Antagonists ; Piperazines - therapeutic use ; Piperidines - therapeutic use ; postoperative nausea and vomiting ; Receptors, Neurokinin-2 - antagonists & inhibitors ; Receptors, Neurokinin-3 - antagonists & inhibitors ; schizophrenia ; Sleep Initiation and Maintenance Disorders - drug therapy ; tachykinin antagonists</subject><ispartof>Expert opinion on investigational drugs, 2009-12, Vol.18 (12), p.1843-1864</ispartof><rights>Informa UK Ltd 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c471t-a7a9e457267be438c2e151ec26351ef5cbb5598b96d5dcbd8d234a847f4bc1323</citedby><cites>FETCH-LOGICAL-c471t-a7a9e457267be438c2e151ec26351ef5cbb5598b96d5dcbd8d234a847f4bc1323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1517/13543780903379530$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1517/13543780903379530$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,59646,59752,60435,60541,61220,61255,61401,61436</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19938899$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Quartara, Laura</creatorcontrib><creatorcontrib>Altamura, Maria</creatorcontrib><creatorcontrib>Evangelista, Stefano</creatorcontrib><creatorcontrib>Maggi, Carlo A</creatorcontrib><title>Tachykinin receptor antagonists in clinical trials</title><title>Expert opinion on investigational drugs</title><addtitle>Expert Opin Investig Drugs</addtitle><description>Tachykinins (TKs) are small peptides widely distributed in the central and peripheral nervous systems where they act as neurotransmitters. Potent and selective TKs antagonists have been developed in the last 20 years and many efforts have been made to prove their efficacy in the treatment of various diseases. Herein the most prominent results in the clinical development are reported and discussed. For aprepitant, the only compound of this class to have been launched to date, results of clinical studies and postmarketing cost-effectiveness data for the treatment of chemotherapy-induced emesis are discussed. The field is still well active, as currently proof-of-concept studies for indications initially missed (i.e., depression) are ongoing and new targets are under investigation.</description><subject>Antiemetics - therapeutic use</subject><subject>anxiety</subject><subject>Asthma - drug therapy</subject><subject>chemotherapy-induced emesis</subject><subject>clinical development</subject><subject>Clinical Trials as Topic</subject><subject>depression</subject><subject>Gastrointestinal Diseases - drug therapy</subject><subject>Humans</subject><subject>irritable bowel syndrome</subject><subject>Mental Disorders - drug therapy</subject><subject>Morpholines - therapeutic use</subject><subject>Neurokinin-1 Receptor Antagonists</subject><subject>Piperazines - therapeutic use</subject><subject>Piperidines - therapeutic use</subject><subject>postoperative nausea and vomiting</subject><subject>Receptors, Neurokinin-2 - antagonists & inhibitors</subject><subject>Receptors, Neurokinin-3 - antagonists & inhibitors</subject><subject>schizophrenia</subject><subject>Sleep Initiation and Maintenance Disorders - drug therapy</subject><subject>tachykinin antagonists</subject><issn>1354-3784</issn><issn>1744-7658</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1KAzEUhYMotlYfwI3MztVoMkkmCbqR4h8U3NR1yGQyNnUmqUkG6dsbaUFEcHUu937ncDkAnCN4hShi1whTghmHAmLMBMXwAEwRI6RkNeWHec73MgNkAk5iXENYwUwdgwkSAnMuxBRUS6VX23frrCuC0WaTfCiUS-rNOxtTLPJe9_msVV-kYFUfT8FRl8Wc7XUGXh_ul_OncvHy-Dy_W5SaMJRKxZQwhLKqZo0hmOvK5KeNrmqcpaO6aSgVvBF1S1vdtLytMFGcsI40GuEKz8DlLncT_MdoYpKDjdr0vXLGj1EyTBBlkONMoh2pg48xmE5ugh1U2EoE5XdT8k9T2XOxTx-bwbQ_jn01GbjdAdZ1Pgzq04e-lUltex-6oJy2UeL_8m9-2VdG9WmlVTBy7cfgcnP_fPcFsrmIiQ</recordid><startdate>20091201</startdate><enddate>20091201</enddate><creator>Quartara, Laura</creator><creator>Altamura, Maria</creator><creator>Evangelista, Stefano</creator><creator>Maggi, Carlo A</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20091201</creationdate><title>Tachykinin receptor antagonists in clinical trials</title><author>Quartara, Laura ; Altamura, Maria ; Evangelista, Stefano ; Maggi, Carlo A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-a7a9e457267be438c2e151ec26351ef5cbb5598b96d5dcbd8d234a847f4bc1323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Antiemetics - therapeutic use</topic><topic>anxiety</topic><topic>Asthma - drug therapy</topic><topic>chemotherapy-induced emesis</topic><topic>clinical development</topic><topic>Clinical Trials as Topic</topic><topic>depression</topic><topic>Gastrointestinal Diseases - drug therapy</topic><topic>Humans</topic><topic>irritable bowel syndrome</topic><topic>Mental Disorders - drug therapy</topic><topic>Morpholines - therapeutic use</topic><topic>Neurokinin-1 Receptor Antagonists</topic><topic>Piperazines - therapeutic use</topic><topic>Piperidines - therapeutic use</topic><topic>postoperative nausea and vomiting</topic><topic>Receptors, Neurokinin-2 - antagonists & inhibitors</topic><topic>Receptors, Neurokinin-3 - antagonists & inhibitors</topic><topic>schizophrenia</topic><topic>Sleep Initiation and Maintenance Disorders - drug therapy</topic><topic>tachykinin antagonists</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Quartara, Laura</creatorcontrib><creatorcontrib>Altamura, Maria</creatorcontrib><creatorcontrib>Evangelista, Stefano</creatorcontrib><creatorcontrib>Maggi, Carlo A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Expert opinion on investigational drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Quartara, Laura</au><au>Altamura, Maria</au><au>Evangelista, Stefano</au><au>Maggi, Carlo A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tachykinin receptor antagonists in clinical trials</atitle><jtitle>Expert opinion on investigational drugs</jtitle><addtitle>Expert Opin Investig Drugs</addtitle><date>2009-12-01</date><risdate>2009</risdate><volume>18</volume><issue>12</issue><spage>1843</spage><epage>1864</epage><pages>1843-1864</pages><issn>1354-3784</issn><eissn>1744-7658</eissn><abstract>Tachykinins (TKs) are small peptides widely distributed in the central and peripheral nervous systems where they act as neurotransmitters. Potent and selective TKs antagonists have been developed in the last 20 years and many efforts have been made to prove their efficacy in the treatment of various diseases. Herein the most prominent results in the clinical development are reported and discussed. For aprepitant, the only compound of this class to have been launched to date, results of clinical studies and postmarketing cost-effectiveness data for the treatment of chemotherapy-induced emesis are discussed. The field is still well active, as currently proof-of-concept studies for indications initially missed (i.e., depression) are ongoing and new targets are under investigation.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>19938899</pmid><doi>10.1517/13543780903379530</doi><tpages>22</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1354-3784 |
| ispartof | Expert opinion on investigational drugs, 2009-12, Vol.18 (12), p.1843-1864 |
| issn | 1354-3784 1744-7658 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_734157083 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | Antiemetics - therapeutic use anxiety Asthma - drug therapy chemotherapy-induced emesis clinical development Clinical Trials as Topic depression Gastrointestinal Diseases - drug therapy Humans irritable bowel syndrome Mental Disorders - drug therapy Morpholines - therapeutic use Neurokinin-1 Receptor Antagonists Piperazines - therapeutic use Piperidines - therapeutic use postoperative nausea and vomiting Receptors, Neurokinin-2 - antagonists & inhibitors Receptors, Neurokinin-3 - antagonists & inhibitors schizophrenia Sleep Initiation and Maintenance Disorders - drug therapy tachykinin antagonists |
| title | Tachykinin receptor antagonists in clinical trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T09%3A47%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tachykinin%20receptor%20antagonists%20in%20clinical%20trials&rft.jtitle=Expert%20opinion%20on%20investigational%20drugs&rft.au=Quartara,%20Laura&rft.date=2009-12-01&rft.volume=18&rft.issue=12&rft.spage=1843&rft.epage=1864&rft.pages=1843-1864&rft.issn=1354-3784&rft.eissn=1744-7658&rft_id=info:doi/10.1517/13543780903379530&rft_dat=%3Cproquest_pubme%3E734157083%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734157083&rft_id=info:pmid/19938899&rfr_iscdi=true |